Ask about this productRelated genes to: GUCA1A antibody
- Gene:
- GUCA1A NIH gene
- Name:
- guanylate cyclase activator 1A
- Previous symbol:
- GUCA, GUCA1, C6orf131
- Synonyms:
- GCAP, GCAP1, COD3, dJ139D8.6, CORD14
- Chromosome:
- 6p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-08
- Date modifiied:
- 2015-11-19
Related products to: GUCA1A antibody
Related articles to: GUCA1A antibody
- Retinopathy of prematurity (ROP), the leading cause of childhood blindness, is considered a vascular retinopathy; however, clinical studies have reported persistent electrophysiological dysfunctions in some ROP patients with remitted vasculopathy, resulting in severe visual impairments. Therefore, this study sought to unravel the mechanisms underlying persistent electrophysiological dysfunctions and identify a neuronal target in a murine model of oxygen-induced retinopathy (OIR), a widely used animal model for ROP. - Source: PubMed
Publication date: 2026/04/29
Yang QianhuiWang JindanWu TongruiLiu SiyiZhang YuminWang XinglongZhang WeiranRong HuaWu MengyuZhao YatingCao YunshanZhang MinShen HuiZhang Yan - Glioma remains a major clinical challenge due to its molecular heterogeneity and limited therapeutic options. While numerous biomarker and drug discovery efforts exist, most are restricted by small sample sizes, subtype-agnostic analyses, or limited integration of computational strategies. Here, we present an integrative machine learning-based systems pipeline for the identification of subtype-specific biomarkers and repurposed therapeutics for glioblastoma (GBM) and low-grade glioma (LGG). We report high-confidence, subtype-specific biomarker candidates by harnessing publicly available gene expression datasets and systematic analyses with oversampling strategies to balance class distributions, followed by feature selection algorithms. Specifically, 10 candidate genes with strong diagnostic potential were identified, including , , , , , , , and for GBM and and for LGG. Repurposed drug candidates were then predicted via signature-based prioritization and evaluated using molecular docking simulations, revealing six promising compounds for GBM (vandetanib, capecitabine, melatonin, agomelatine, ramelteon, and tasimelteon) and one for LGG (ambroxol). This study demonstrates the utility of combining class-balancing, feature selection, and drug repurposing pipelines to uncover clinically relevant glioma biomarkers and therapeutic candidates, thus providing a computational foundation for future experimental and translational validation in these brain cancers and neuro-oncology. - Source: PubMed
Publication date: 2025/12/24
Soyer Semra MelisKizilay Elif BenguOzbek PemraKasavi Ceyda - Hematopoietic stem cells (HSCs) possess the ability to long term reconstitute all the blood lineages and generate all blood cell types. As such, the in vitro generation of HSCs remains a central goal in regenerative medicine. Despite many efforts and recent advancements in the field, there is still no robust, reproducible, and efficient protocol for generating bona fide HSCs in vitro. This suggests that certain regulatory elements have yet to be uncovered. Here, we present a novel and unbiased approach to identifying endogenous components to specify HSCs from pluripotent stem cells. We performed a genomewide CRISPR activator screening during mesodermal differentiation from mouse embryonic stem cells. After in vitro differentiation, mesodermal KDR+ precursors were transplanted into primary and secondary immunodeficient NSG mice. This approach led to the identification of 7 genes (Spata2, Aass, Dctd, Eif4enif1, Guca1a, Eya2, and Net1) that, when activated during mesoderm specification, induce the generation of hematopoietic stem and progenitor cells. These cells are capable of serial engraftment and multilineage output (erythroid, myeloid, and T and B lymphoid) in vivo. Single-cell RNA sequencing further revealed that activating these 7 genes biases the embryoid bodies toward intraembryonic development, instead of extraembryonic, increasing the number of mesodermal progenitors that can generate HSCs. Our findings underscore the importance of differentiation during the first germ layer specification to generate definitive blood stem cells. - Source: PubMed
Palma Luis GKartha Gayathri MMaqueda MariaBarrero MercedesCanton EricIglesias ArnauGonzález JessicaHerrero-Molinero PatriciaTorres-Ruiz RaúlPayer BernhardBueno ClaraMenéndez PabloEspinosa LluisBigas Anna - Phototransduction, the process by which captured photons elicit electrical changes in retinal rod and cone cells, represents the first neuronal step in vision and involves interactions between several highly specialised proteins. Pathogenic variants in genes encoding many of these proteins can give rise to significant vision impairment, accounting for a substantial portion of inherited retinal disease. Such genes include RHO, OPN1LW, OPN1MW, GNAT1, GNAT2, GNB3, PDE6A, PDE6B, PDE6G, PDE6C, PDE6H, CNGA1, CNGB1, CNGA3, CNGB3, GRK1, SAG, ARR3, RGS9, RGS9BP, GUCY2D, GUCA1A and SLC24A1. Many of these conditions have distinct mechanisms and clinical features. They follow several modes of inheritance (including in one case digenic, or tri-allelic, inheritance). Some conditions also entail myopia. Rod and cone phototransduction will be outlined, followed by the discussion of diseases associated with these genes. Some phenotypic features will be highlighted as well as their prevalence in a large genotyped inherited retinal disease cohort. - Source: PubMed
Publication date: 2025/02/27
Wong Wendy MMahroo Omar A - To report findings in GUCA1A-associated retinopathy, a rare autosomal-dominant retinopathy. - Source: PubMed
Allon GiladLin SiyingRobson Anthony GArno GavinNeveu Magella MHysi Pirro GMichaelides MichelWebster Andrew RMahroo Omar A